Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -6.40 -0.43% 1,486.00 1,485.60 1,486.20 1,502.00 1,484.80 1,500.00 527,078 08:23:08
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 34,114.0 5,442.0 87.6 17.0 60,441

Gsk Share Discussion Threads

Showing 30901 to 30925 of 31525 messages
Chat Pages: Latest  1237  1236  1235  1234  1233  1232  1231  1230  1229  1228  1227  1226  Older
DateSubjectAuthorDiscuss
24/8/2022
09:24
net
I think you are being a bit hard. GSK was in recession before it became global.

jonjoneil
24/8/2022
08:44
Porsche is just a troll , posting same pointless rant on other LSE forum , pretty sad really
alibizzle
24/8/2022
08:16
Entire global stockmarket tanking and same idiots on this board blame the GSK directors for global recession.
Talk about crazy investors.

netcurtains
24/8/2022
08:05
If you want to know the latest share price, don't look at the GSK website. They haven't updated the UK market price. Current price showing £14.25 at close on the 19th. Are they trying to hide something?
jonjoneil
24/8/2022
07:21
Board change but not the one that's needed
spoole5
23/8/2022
12:59
Can't agree less!
tradermichael
23/8/2022
12:49
@traderM. Well they would say that wouldnt they? How is this still over 14 quid. Guessing sub 12 soon, whole UK and its indexes heading for toilet anyway with sterling collapsing nobody wants U.K. assets but gsk in the shxt with this, its been known for an age there has been issues with various cancers from ranitidine. The stuff is poison and causes other issues as well. Years this will go on for.
porsche1945
23/8/2022
11:40
Sadly the investors are not convinced hence the crashing continues .
abdullla
23/8/2022
11:18
There was a payout of $500,000 from generic companies to Bayer . I think there will be a significant cost to GSK down the line , and all the uncertainty isn't good for the share price Tbh i have had a big loss but will keep collecting dividends for next year or beyond until I get my initial investment back. Been depressing viewing recently . Altho it was in the brochure I didn't read it all and wasn't mentioned here so was unaware of zantac litigation otherwise would haven't bought in pre split
alibizzle
23/8/2022
10:57
USD 1.18 = £1.00 is working well for GSK .... ;0)
tradermichael
23/8/2022
10:47
Thanks Tm .
abdullla
23/8/2022
10:02
The overwhelming weight of the scientific evidence supports the conclusion that there is no increased cancer risk associated with the use of ranitidine,” GSK has asserted.

“GSK will continue to vigorously defend itself against all claims alleging otherwise".

tradermichael
23/8/2022
09:57
The first lawsuit claiming that gastrointestinal drug Zantac causes cancer was voluntarily dismissed a week before it was due to come to trial, in an early victory for the pharma companies that will defend themselves from the allegations.

Counsel acting for the plaintiff in the case – Joseph Bayer – filed for dismissal without any settlement payment from GSK, which was named as a defendant in the suit. The company said that it “welcomes this outcome and believes the dismissal of Mr Bayer’s case is the correct result.”

tradermichael
23/8/2022
09:53
What happened to the GSK hearing that was due in the courts today ?
abdullla
22/8/2022
15:42
I still think GSK would be better served under new leadership, even though Emma did well to offload so much debt onto the consumer company (terrible for them however!).
Have kept watch here to see how things would settle down, but this latest news regarding the possible litigation is making it difficult to ascribe value/risk, for me anyway. Will continue a watching brief for now, although GSK held up well today. GLA.

lovewinshatelosses
22/8/2022
09:10
"Clouds are gathering(again) for GSK"
Summary TEL Investment Research

GSK was having a turnaround year, with drugs pipeline strong and H1 results impressive.

Zantac lawsuits are presenting a significant risk to investing in GSK.
Haleon's public offering was underwhelming.

hTTps://seekingalpha.com/article/4536062-gsk-clouds-are-gathering-again?

The once blockbuster stress-relief drug of GSK is facing increasingly significant lawsuits in the United States. While the lawsuits have been rolling on for a while, analyst reports by Morgan Stanley and other banks were published over the past days, highlighting significant litigation risks. Morgan Stanley estimated that damages could reach up to USD 45 billion, out of which around 60% would be charged to GSK – about a third of GSK’s market cap, and five times its net income in 2021.


vs

Morningstar Analyst Note | Damien Conover, CFA | Aug 11, 2022
Shares of GSK and Sanofi are under pressure due to increasing concerns regarding legal cases related to a potential cancer side effect from the over-the-counter heartburn medicine Zantac, according to several news sources.

We view the pressure as overdone, as we do not expect major legal settlements regarding the medicine. We are not changing our fair value estimates for the companies as we have already factored in minor payouts related to drug liabilities for both companies.

Also, we do not expect this ongoing litigation to have an impact on the moats of GSK or Sanofi, which are much more related to strong innovation with prescription drugs that should not be affected by the Zantac legal issues.

The implied market capitalization losses for these companies of over $30 billion potentially due to the Zantac legal concerns seems too high. Litigation around drug side effects is not uncommon in the U.S., but a payout amount suggested by the stock price declines at GSK and Sanofi would seem extraordinary. For reference, most drug side-effect settlements range from nothing to low double-digit millions of dollars. The largest drug settlements due to side effects tend to range from $2 billion to $7 billion. However, the opioid settlements for Purdue Pharma, Teva, Johnson & Johnson, and Mallinckrodt totaled close to $20 billion. However, the Zantac issues look less damaging for Sanofi and GSK. While Zantac was removed from the U.S. market close to two years ago due to potential carcinogenic effects, the strong safety profile of the drug in previous decades (drug was launched in 1981) suggests challenging legal hurdles for plaintiffs. Also, other firms have distributed Zantac, which may reduce the legal pressures for GSK and Sanofi.

As far as next steps, we expect Zantac litigation cases to begin later in 2022 and into 2023. We expect a prolonged litigation process as involved companies will likely litigate these cases one by one partly because of the slow legal system.

geckotheglorious
22/8/2022
07:33
So far so good. No one breath.
netcurtains
21/8/2022
17:38
MD: On 27 July, at Q2 results, it was confirmed:

GSK also announced a 16.25p dividend, versus its second-quarter dividend payment in 2021, which was 23.75p.

This was all connected with the consolidation at the time of the demerger.

tradermichael
21/8/2022
14:37
'No change to expected dividend of 61.25p/share (49p before Share Consolidation) for FY 2022'

Was looking to re-enter at these levels, but dividend yield is only 4% despite the big shareprice decline ?

mister md
19/8/2022
16:25
EI, That was always the case. If you think about it, it makes GSK far more secure as it implies that GSK is unlikely to be liable for any generic versions - that is a huge slab of the whole lot!

I guess that implies where the litigation is revolving is likely to be around the wording on the packet, not so much the known ingredients (eg perhaps a lack of warning labels?)

netcurtains
19/8/2022
13:59
On the dropped US litigation case.

"Bloomberg reports that generic firms including Israel’s Teva, Dr Reddy’s Laboratories and others agreed to pay the plaintiff $500,000 (£415,000) to stop the matter going to trial.."

essentialinvestor
19/8/2022
13:57
AZN very near a new all time high
netcurtains
19/8/2022
13:38
PUBLISHED: 22:19, 17 August 2022 ..... overreaction
tradermichael
19/8/2022
12:52
from today's Mail:-
"Haleon is just the latest in a line of IPO flops damaging the reputation of the London Stock Exchange"


hTTps://www.dailymail.co.uk/money/comment/article-11120833/ALEX-BRUMMER-Haleons-IPO-flop-damages-London-Stock-Exchange.html

jonjoneil
19/8/2022
09:57
Added again.Volatility is getting more muted.Hoping the 1371p last week was the capitulation trade.Time will tell.Recovery or more falls to come?
redbaron10
Chat Pages: Latest  1237  1236  1235  1234  1233  1232  1231  1230  1229  1228  1227  1226  Older
Your Recent History
LSE
GSK
Gsk
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221208 08:38:11